Biden Agrees To Let High Prices Drive March-In Rights, But Advocates Still Wary

By Maaisha Osman / December 7, 2023 at 9:05 AM
Updated Story The Biden administration has decided to change long-standing policy and let high drug prices be a reason to step in and seize patents under rarely used march-in-rights, following years of pressure from drug-price control advocates to do so. But drug-pricing advocates said they plan to closely scrutinize the administration’s new march-in framework, unveiled Thursday morning (Dec. 7) for public comment, saying the details will determine whether the policy shift is ultimately useful in fighting monopoly...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.